Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global healthcare budgets.

Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential ...

CVS is far from the only one with interest in making cheaper versions of popular prescription drugs. Biosimilar versions of Humira, specifically, have been top of mind for drug companies and ...

A provision in 2022's Inflation Reduction Act injected massive uncertainty into the biosimilar market, and could keep dozens of cost-saving biosimilars from ever making it to patients.

A systematic literature review published in JAMA Dermatology provides proof that biosimilar drugs are safe and effective in treating psoriasis.An analysis of clinical studies that compared ...

The five biosimilar entrants not only entered with lower price points, but within three years, they saw declines on their ASP ranging from 28% to 58% of Herceptin’s pre-competition ASP. Even steeper ...

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what ...

Drugmaker Amgen on Tuesday launched a biosimilar to the widely-prescribed Humira, giving consumers an alternative to the world's top-selling rheumatoid arthritis drug.. The new drug, Amjevita ...

The most advanced rBIO program is biosimilar insulin, but it still needs to go through clinical testing. The startup’s founders have a goal of lowering the cost of insulin by 30% . New ...

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leader in pharmacy benefits automation, today announces the launch of its all-new Biosimilar Dashboard, a real-time analytics tool designed to streamline ...

Biosimilar savings could total $124.5 billion from 2021 to 2025, a 2022 study by RAND Corp. researchers estimated. But the savings will hinge on adoption rates and if federal regulators crack down ...

Enter biosimilar medications. These medications are near copies of biologic medications with (typically) a much lower price tag. It’s easy to wonder if less expensive means they’re less effective.